Fimepinostat

DB11891InvestigationalSmall molecule

Fimepinostat (CUDC-907) has been used in trials studying the treatment of lymphoma, solid tumors, breast cancer, multiple myeloma, and NUT midline carcinoma, among others.

Mechanism: Pharmacologically active on Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform, Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform, and Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform
Curator reviewed
Formula / weight: C₂₃H₂₄N₈O₄S · 508.56 g/mol (avg)
Also known as: PI3K/HDAC inhibitor CUDC-907
Code names: CUDC-907

Resolves to

Compound

UNII3S9RX35S5XCAS1339928-25-4ChEMBLCHEMBL3622533PubChem54575456

Structure

InChIKeyJOWXJLIFIIOYMS-UHFFFAOYSA-NSMILESCOC1=CC=C(C=N1)C1=NC(N2CCOCC2)=C2SC(CN(C)C3=NC=C(C=N3)C(=O)NO)=CC2=N1

Targets

P42336PIK3CAO00329PIK3CDP42338PIK3CBP48736PIK3CG

What you can answer from here — as of July 17, 2026

5Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

424Drug interactionsStructured to mechanism, not free text

7Clinical trialsPhase, status and sponsor resolved per trial

15+ReferencesStructured and connected to the statements they support

Which drugs share a target with Fimepinostat, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account